Abstract
Eg5 is a motor protein belonging to the kinesin-5 family and has been suggested to exert important function in tumors. In this study, we determined the mRNA and protein expression levels of Eg5 in cancerous and non-cancerous breast tissue by quantitative real-time polymerase chain reaction (qRT-PCR) and tissue microarray immunohistochemistry analysis (TMA-IHC) respectively. The results of 20 fresh-frozen BC samples demonstrated that Eg5 mRNA levels were significantly higher in BC tissues compared with corresponding non-cancerous tissue (p = 0.0009). TMA-IHC analysis in 127 BC tissues revealed that Eg5 expression obviously correlated with clinicopathologial parameters, including tumor grade (p = 0.004), ER status (p = 0.030), Ki67 status (p = 0.005), molecular classification (p = 0.026), N stage (p = 0.015), and TNM stage (p = 0.001). Kaplan-Meier survival curve indicated that high Eg5 expression (p = 0.012), Ki67 status (p = 0.014) and TNM stage (p = 0.026) were independent factors to predict poor prognosis for patients with breast cancer. Our data suggest that Eg5 is not only overexpressed in BC, it may be also served as a potential prognostic marker.
Highlights
Breast cancer (BC) is one of the most common types of cancers among women; it affects over 1.3 million new patients and causes nearly 0.5 million deaths each year [1]
The results of 20 freshfrozen BC samples demonstrated that Eg5 mRNA levels were significantly higher in BC tissues compared with corresponding non-cancerous tissue (p = 0.0009)
The expression of Eg5 mRNA was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) in BC tissue samples as well as in corresponding non-cancerous tissue samples obtained from 20 BC patients
Summary
Breast cancer (BC) is one of the most common types of cancers among women; it affects over 1.3 million new patients and causes nearly 0.5 million deaths each year [1]. BC is usually classified into several types on the basis of molecular signatures, clinicopathological characteristics, and treatment responses [4]. A large number of BC criteria are routinely and widely acknowledged in the clinical field, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2), Ki67 proliferative index, TNM stage, tumor grade, metastatic status and molecular classification have been suggested for prognosis [7]. Novel biomarkers are needed to optimize the treatment strategy, evaluate the therapeutic effectiveness, and predict the clinical outcomes of BC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
